Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement.

Lievens Y, Defourny N, Corral J, Gasparotto C, Grau C, Borras JM; ESTRO–HERO Consortium Collaborators.

Lancet Oncol. 2020 Jan;21(1):e42-e54. doi: 10.1016/S1470-2045(19)30794-6. Review.

PMID:
31908306
2.

Evolution of self-perceived swallowing function, tongue strength and swallow-related quality of life during radiotherapy in head and neck cancer patients.

Van den Steen L, Van Gestel D, Vanderveken O, Vanderwegen J, Lazarus C, Daisne JF, Van Laer C, Specenier P, Van Rompaey D, Mariën S, Lawson G, Chantrain G, Desuter G, Van den Weyngaert D, Cvilic S, Beauvois S, Allouche J, Delacroix L, Vermorken JB, Peeters M, Dragan T, Van de Heyning P, De Bodt M, Van Nuffelen G.

Head Neck. 2019 Jul;41(7):2197-2207. doi: 10.1002/hed.25684. Epub 2019 Feb 14.

PMID:
30793811
3.

In Regard to Bibault et al.

Daisne JF, Nuyts S, Duprez F, Bihin B.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):807-808. doi: 10.1016/j.ijrobp.2017.11.039. No abstract available.

PMID:
29413296
4.

Dose de-escalation to the elective lymph nodes in head and neck cancer. Reply to Amdur et al.

Nevens D, Duprez F, Daisne JF, De Neve W, Nuyts S.

Radiother Oncol. 2017 Aug;124(2):336. doi: 10.1016/j.radonc.2017.07.003. Epub 2017 Jul 24. No abstract available.

PMID:
28751230
5.

Feasibility of tongue strength measurements during (chemo)radiotherapy in head and neck cancer patients.

Van den Steen L, Vanderveken O, Vanderwegen J, Van Gestel D, Daisne JF, Allouche J, Delacroix L, Van Rompaey D, Beauvois S, Cvilic S, Mariën S, Desuter G, Vermorken JB, Van den Weyngaert D, Specenier P, Van Laer C, Peeters M, Van de Heyning P, Chantrain G, Lawson G, Lazarus C, De Bodt M, Van Nuffelen G; Member of the Belgian Cancer Plan 29_033_Dysphagia Group.

Support Care Cancer. 2017 Nov;25(11):3417-3423. doi: 10.1007/s00520-017-3761-1. Epub 2017 Jun 2.

PMID:
28573486
6.

Recurrence patterns after a decreased dose of 40Gy to the elective treated neck in head and neck cancer.

Nevens D, Duprez F, Daisne JF, Schatteman J, Van der Vorst A, De Neve W, Nuyts S.

Radiother Oncol. 2017 Jun;123(3):419-423. doi: 10.1016/j.radonc.2017.03.003. Epub 2017 Mar 22.

PMID:
28342647
7.

Radiotherapy induced dermatitis is a strong predictor for late fibrosis in head and neck cancer. The development of a predictive model for late fibrosis.

Nevens D, Duprez F, Daisne JF, Laenen A, De Neve W, Nuyts S.

Radiother Oncol. 2017 Feb;122(2):212-216. doi: 10.1016/j.radonc.2016.08.013. Epub 2016 Sep 20.

PMID:
27663951
8.

Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control.

Nevens D, Duprez F, Daisne JF, Dok R, Belmans A, Voordeckers M, Van den Weyngaert D, De Neve W, Nuyts S.

Radiother Oncol. 2017 Feb;122(2):171-177. doi: 10.1016/j.radonc.2016.08.009. Epub 2016 Aug 12.

PMID:
27528118
9.

Validation of the total dysphagia risk score (TDRS) in head and neck cancer patients in a conventional and a partially accelerated radiotherapy scheme.

Nevens D, Deschuymer S, Langendijk JA, Daisne JF, Duprez F, De Neve W, Nuyts S.

Radiother Oncol. 2016 Feb;118(2):293-7. doi: 10.1016/j.radonc.2015.10.008. Epub 2015 Oct 20.

PMID:
26477396
10.

Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy.

Leclerc M, Lartigau E, Lacornerie T, Daisne JF, Kramar A, Grégoire V.

Radiother Oncol. 2015 Jul;116(1):87-93. doi: 10.1016/j.radonc.2015.06.007. Epub 2015 Jun 15.

PMID:
26088157
11.

Intramedullary spinal cord metastasis of cholangiocarcinoma: a case report.

Faugeras L, Cantineau G, Daisne JF, Gustin T, D'hondt L.

BMC Res Notes. 2015 Feb 14;8:41. doi: 10.1186/s13104-015-0998-y.

12.

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.

Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, Daisne JF, Yunes Ancona AC, Cmelak A, Mesía R, Zhang A, Oliner KS, VanderWalde A.

Lancet Oncol. 2015 Feb;16(2):221-32. doi: 10.1016/S1470-2045(14)71200-8. Epub 2015 Jan 15.

PMID:
25596659
13.

Early prediction of response to cetuximab and radiotherapy by FDG-PET/CT for the treatment of a locoregionally advanced squamous cell carcinoma of the hypopharynx.

Grybauskas M, Daisne JF, Aleknavičius E, Burneckis A.

Medicina (Kaunas). 2014;50(4):245-8. doi: 10.1016/j.medici.2014.09.003. Epub 2014 Sep 29.

14.

Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer.

Mardjuadi FI, Carrasco J, Coche JC, Sempoux C, Jouret-Mourin A, Scalliet P, Goeminne JC, Daisne JF, Delaunoit T, Vuylsteke P, Humblet Y, Meert N, van den Eynde M, Moxhon A, Haustermans K, Canon JL, Machiels JP.

Target Oncol. 2015 Sep;10(3):375-83. doi: 10.1007/s11523-014-0342-9. Epub 2014 Oct 11.

PMID:
25304881
15.

SPECT/CT lymphoscintigraphy of sentinel node(s) for superselective prophylactic irradiation of the neck in cN0 head and neck cancer patients: a prospective phase I feasibility study.

Daisne JF, Installé J, Bihin B, Laloux M, Vander Borght T, Mathieu I, Lawson G.

Radiat Oncol. 2014 May 28;9:121. doi: 10.1186/1748-717X-9-121.

16.

Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity.

Nuyts S, Lambrecht M, Duprez F, Daisne JF, Van Gestel D, Van den Weyngaert D, Platteaux N, Geussens Y, Voordeckers M, Madani I, De Neve W.

Radiother Oncol. 2013 Nov;109(2):323-9. doi: 10.1016/j.radonc.2013.06.044. Epub 2013 Aug 13.

PMID:
23953410
17.

Atlas-based automatic segmentation of head and neck organs at risk and nodal target volumes: a clinical validation.

Daisne JF, Blumhofer A.

Radiat Oncol. 2013 Jun 26;8:154. doi: 10.1186/1748-717X-8-154.

18.

Stereotactic radiosurgery for the management of brain metastases.

D'Hondt L, Daisne JF, Gustin T.

N Engl J Med. 2010 Aug 5;363(6):591-2; author reply 592-3. doi: 10.1056/NEJMc1005003. No abstract available.

PMID:
20836238
19.

A practice survey of the evolution of rectal cancer management: a Belgian Federal College of radiotherapy study.

Magné N, Daisne JF, Moretti L, Berben D, Meert N, Alen R, Bral S, Cleef AV, Haustermans K, Houtte PV, Scalliet P.

Bull Cancer. 2009 Jul-Aug;96(7):E45-51. doi: 10.1684/bdc.2009.0914.

20.

[Multimodalities imaging for target volume definition in radiotherapy].

Daisne JF, Grégoire V.

Bull Cancer. 2006 Dec;93(12):1175-82. Review. French.

Supplemental Content

Loading ...
Support Center